Cerevel Therapeutics Holdings Insiders Placed Bullish Bets Worth US$2.51m

Quite a few insiders have dramatically grown their holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) over the past 12 months. An insider's optimism about the company's prospects is a posit

Simply Wall StApr 30 20:04

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease. The TEMPO-3 trial evaluated the effi

BenzingaApr 19 01:44

Cerevel (CERE.US), acquired by ABBV.US (ABBV.US), achieves key targets for advanced Parkinson's disease drugs

Cerevel Therapeutics announced Thursday that its once-a-day oral drug candidate for Parkinson's disease, tavapadon, has achieved key goals in a key phase 3 trial as a combination therapy.

Zhitong FinanceApr 18 21:25

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

Health care stocks were mixed pre-bell Thursday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.4% higher. Elevance Health (ELV) stock was up mo

MT NewswiresApr 18 21:12

AbbVie Buyout Cerevel Posts Late-stage Win for Parkinson's Disease Drug

Seeking AlphaApr 18 19:00

Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo

Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Withou

BenzingaApr 18 18:34